FDA warns South Korea's Green Pharmaceutical over OTC drug CGMP failures, including missing identity testing and weak quality unit.
What happened
FDA reviewed records Green Pharmaceutical submitted after FDA's March 3, 2023 request under section 704(a)(4); there was no inspection. FDA found the company did not test each incoming component lot for identity, including high-risk components, and its quality unit did not properly approve or reject components. FDA cited CGMP violations and placed the firm on Import Alert 66-40 on July 17, 2023.
What FDA found
The firm did not perform at least one identity test on each incoming component lot, including high-risk components, to confirm identity and safety limits.
21 CFR 211.84(d)(1)The firm's quality unit did not adequately exercise its authority to approve or reject components and oversee quality.
21 CFR 211.22(a)
What FDA wants
FDA asks the company to respond in writing within 30 working days and to provide certain high-risk component test results within 30 calendar days, along with a risk assessment and corrective actions. FDA also recommends a qualified CGMP consultant if the firm intends to resume making drugs for the U.S. market.
Who should pay attention
- US brands and importers of OTC drugs made by this firm
- distributors sourcing South Korean OTC drug products
- drugmakers using high-risk raw materials that require identity testing
This is a summary. Read the original letter on fda.gov.